Giamarellou H, Sahin A, Chryssouli Z
Drugs Exp Clin Res. 1987;13(3):149-53.
The in vitro activity of the new parenteral cephalosporin BMY-28142 was compared with that of cephalothin, cefoxitin, cefotaxime, ceftriaxone, moxalactam, aztreonam and ceftazidime, against a total of 374 recent multiresistant Gram-negative microorganisms of nosocomial origin. Against all species of Enterobacteriaceae resistant to the first- and second-generation cephalosporins, BMY-28142 had superior inhibitory activity than the newer beta-lactams tested, with intrinsic activity against E. coli and Pr. mirabilis slightly less than that of cefotaxime and ceftriaxone. BMY-28142 differed from the other beta-lactams mainly in being at least 16-fold more active against E. cloacae, while BMY-28142 and ceftazidime showed comparable activity against Ps. aeruginosa strains. Against strains of Ps. aeruginosa resistant to both BMY-28142 and amikacin, the combination of the two antibiotics proved to be synergistic in vitro.
将新型胃肠外头孢菌素BMY - 28142的体外活性与头孢噻吩、头孢西丁、头孢噻肟、头孢曲松、拉氧头孢、氨曲南和头孢他啶进行了比较，受试对象为总共374株近期源自医院的多重耐药革兰氏阴性微生物。对于所有对第一代和第二代头孢菌素耐药的肠杆菌科细菌，BMY - 28142的抑制活性优于所测试的新型β - 内酰胺类药物，其对大肠杆菌和奇异变形杆菌的固有活性略低于头孢噻肟和头孢曲松。BMY - 28142与其他β - 内酰胺类药物的主要区别在于，它对阴沟肠杆菌的活性至少高16倍，而BMY - 28142和头孢他啶对铜绿假单胞菌菌株的活性相当。对于对BMY - 28142和阿米卡星均耐药的铜绿假单胞菌菌株，两种抗生素的组合在体外显示出协同作用。
